Drug class in one race
KRAS G12C drugs for Non-Small Cell Lung Cancer
10 tracked KRAS G12C drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the KRAS G12C page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 44 Phase 31 Phase 22 Phase 1/22 Phase 1
Head-to-head evidence: BBO-8520 vs Fulzerasib · BBO-8520 vs Glecirasib · BBO-8520 vs Sotorasib · Calderasib vs Fulzerasib · Calderasib vs Glecirasib · Calderasib vs Sotorasib